PTPI

Petros Pharmaceuticals Inc. (PTPI) | Rumor.io

Petros Pharmaceuticals

PTPI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization211.9K

Earnings per share6.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)1.9M

Social

What share of all stock conversation is about PTPI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% -0.01

Aug 15

Petros Pharmaceuticals' (PTPI) latest report shows a significant increase in income to $5.4 million and a substantial decrease in debt-to-asset ratio to 39.88%.
The company's cash reserves total $7.3 million, enough to cover the next 12 months, and its stockholders' equity has regained Nasdaq compliance at $4.4 million.
The SEC has rejected Petros Pharmaceuticals' request for a reverse stock split (RS), potentially impacting the company's plans for relisting and FDA news.

Generated by AI

Sentiment

Of the messages about PTPI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	66.07% -13.75
Bearish	0%	0%	0%	33.93% +13.75

Bullish· May 22

PTPI has a high chance of approval and could see a significant price increase once the approval is announced.
The company has a strong financial position with $10 million in cash and a profitable business plan, which could help drive the stock price up.
PTPI has a significant gap to fill, with some analysts predicting a potential price range of $0.10 to $0.32 over the next three months.

Bearish· May 22

The company's management has a poor track record, making it unlikely for the stock to be successful.
The stock is expected to be delisted and will likely decline to a penny stock status.
The company's stock price is highly unstable and may drop below $0.01, with some even predicting it will go to $0.

Generated by AI

Topics

Of the messages about PTPI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	91.06%
Controversies	—	—	—	2.44%
Earnings	—	—	—	4.07%
Macro	—	—	—	0%
Technical Analysis	—	—	—	2.44%

Announcements· May 21

Petros Pharmaceuticals (PTPI) announces transition from NASDAQ to OTC Markets, citing disappointment with delisting determination but plans to appeal.
The company has over $10 million in cash and remains committed to advancing its business plan and increasing stockholder value.
PTPI has partnered with Innolitics to develop an AI-powered SaaS platform targeting OTC drug conversions, with a focus on self-care markets and a completed 1:25 reverse split.

Technical Analysis· May 21

$PTPI has shown a potential breakout, with a possible target of $0.30.
The stock's 30-minute MACD is setting up nicely, indicating a potential buying opportunity.
$PTPI has formed a double bottom pattern, which could lead to a rebound to $0.35 or higher.

Generated by AI

Community

Of the messages about PTPI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	61.47%
Newcomers	100%	100%	100%	38.53%

Regulars· May 21

$PTPI has shown increasing momentum with price targets of $0.25, $0.285, and $0.3, and a key support level at $0.18.
Petros Pharmaceuticals' transition from NASDAQ to OTC Markets has been met with strong negative sentiment, with some participants labeling it "BAD!"
Regulars are closely watching $PTPI's price action, with some setting targets at $0.20 and $0.30, and others monitoring key support and resistance levels at $0.15, $0.20, and $0.214.

Newcomers· May 21

$PTPI is set to be delisted from the Nasdaq and will begin trading on the OTC market, with the company announcing a staff determination letter from Nasdaq.
The company's announcement of a delisting and transition to the OTC market has led to significant trading volume, with some users speculating that the manipulators are trying to run up the stock for an up move.
$PTPI's stock has experienced a significant gain of 50% from after-hours to premarket, with some users speculating that the stock could continue to rise, potentially reaching $5.

Generated by AI

Also Discussed

Investors talking about PTPI also mention

#	Name	Attention
1	Biofrontera Inc.BFRI	0%0
2	Longeveron Inc. Class A Common StockLGVN	0%0
3	iSpecimen Inc.ISPC	0%0
4	Pasithea Therapeutics Corp.KTTA	0%0
5	Society Pass IncorporatedSOPA	0%0
6	Context Therapeutics Inc.CNTX	0%0
7	Ensysce Biosciences, Inc. Common StockENSC	0%0
8	Cumberland Pharmaceuticals Inc.CPIX	0%new
9	Immix Biopharma, Inc.IMMX	0.03%+0.03
10	Kidpik Corp.PIK	0%new

Petros Pharmaceuticals Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals Inc. is a company specializing in the development and commercialization of pharmaceuticals in the field of men's health. Its primary focus is on treatments related to male sexual health, offering innovative solutions designed to enhance quality of life. Notable for its flagship product, Stendra, a prescription medication used to treat erectile dysfunction, Petros Pharmaceuticals aims to deliver impactful therapies that address significant medical needs. Operating within the broader pharmaceutical industry, the company works to expand its market reach through strategic partnerships, research and development initiatives, and novel product offerings. Its role in the market reflects a commitment to advancing health and wellness in specialized areas, contributing to the dynamic landscape of health care solutions. Headquartered in the United States, Petros Pharmaceuticals is an active player in the life sciences sector, continually exploring opportunities to innovate and lead in its specific niche.

Website

Location

1185 Avenue of the Americas

New York, NY, 10036

United States

Social

What share of all stock conversation is about PTPI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% -0.01

Aug 15

Petros Pharmaceuticals' (PTPI) latest report shows a significant increase in income to $5.4 million and a substantial decrease in debt-to-asset ratio to 39.88%.
The company's cash reserves total $7.3 million, enough to cover the next 12 months, and its stockholders' equity has regained Nasdaq compliance at $4.4 million.
The SEC has rejected Petros Pharmaceuticals' request for a reverse stock split (RS), potentially impacting the company's plans for relisting and FDA news.

Generated by AI

Sentiment

Of the messages about PTPI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100%	66.07% -13.75
Bearish	0%	0%	0%	33.93% +13.75

Bullish· May 22

PTPI has a high chance of approval and could see a significant price increase once the approval is announced.
The company has a strong financial position with $10 million in cash and a profitable business plan, which could help drive the stock price up.
PTPI has a significant gap to fill, with some analysts predicting a potential price range of $0.10 to $0.32 over the next three months.

Bearish· May 22

The company's management has a poor track record, making it unlikely for the stock to be successful.
The stock is expected to be delisted and will likely decline to a penny stock status.
The company's stock price is highly unstable and may drop below $0.01, with some even predicting it will go to $0.

Generated by AI

Topics

Of the messages about PTPI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	91.06%
Controversies	—	—	—	2.44%
Earnings	—	—	—	4.07%
Macro	—	—	—	0%
Technical Analysis	—	—	—	2.44%

Announcements· May 21

Petros Pharmaceuticals (PTPI) announces transition from NASDAQ to OTC Markets, citing disappointment with delisting determination but plans to appeal.
The company has over $10 million in cash and remains committed to advancing its business plan and increasing stockholder value.
PTPI has partnered with Innolitics to develop an AI-powered SaaS platform targeting OTC drug conversions, with a focus on self-care markets and a completed 1:25 reverse split.

Technical Analysis· May 21

$PTPI has shown a potential breakout, with a possible target of $0.30.
The stock's 30-minute MACD is setting up nicely, indicating a potential buying opportunity.
$PTPI has formed a double bottom pattern, which could lead to a rebound to $0.35 or higher.

Generated by AI

Community

Of the messages about PTPI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	61.47%
Newcomers	100%	100%	100%	38.53%

Regulars· May 21

$PTPI has shown increasing momentum with price targets of $0.25, $0.285, and $0.3, and a key support level at $0.18.
Petros Pharmaceuticals' transition from NASDAQ to OTC Markets has been met with strong negative sentiment, with some participants labeling it "BAD!"
Regulars are closely watching $PTPI's price action, with some setting targets at $0.20 and $0.30, and others monitoring key support and resistance levels at $0.15, $0.20, and $0.214.

Newcomers· May 21

$PTPI is set to be delisted from the Nasdaq and will begin trading on the OTC market, with the company announcing a staff determination letter from Nasdaq.
The company's announcement of a delisting and transition to the OTC market has led to significant trading volume, with some users speculating that the manipulators are trying to run up the stock for an up move.
$PTPI's stock has experienced a significant gain of 50% from after-hours to premarket, with some users speculating that the stock could continue to rise, potentially reaching $5.

Generated by AI

Petros Pharmaceuticals

Social

Aug 15

Sentiment

Bullish· May 22

Bearish· May 22

Topics

Announcements· May 21

Technical Analysis· May 21

Community

Regulars· May 21

Newcomers· May 21

Also Discussed

Petros Pharmaceuticals Inc.

Company Information

Location

Also Discussed

Social

Aug 15

Sentiment

Bullish· May 22

Bearish· May 22

Topics

Announcements· May 21

Technical Analysis· May 21

Community

Regulars· May 21

Newcomers· May 21